Humoral immune response to polymorphic epithelial mucin (MUC-1) in patients with benign and malignant breast tumours

European Journal of Cancer Part A

Volumn 32, Issue 8, 1996, Pages 1325-1331

  Von Mensdorff Pouilly, S ^a   Gourevitch, M M ^a   Kenemans, P ^a   Verstraeten, A A ^a   Litvinov, S V ^b   Van Kamp, G J ^a   Meijer, S ^a   Vermorken, J ^a   Hilgers, J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Auto antibodies; Breast cancer; CA 15.3; MUC 1; PEM; Prognosis

Indexed keywords

CANCER VACCINE; CELL ADHESION MOLECULE; MUCIN;

ADULT; AGED; ANTIGEN ANTIBODY COMPLEX; ARTICLE; BREAST CANCER; BREAST TUMOR; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS;

EID: 0030017992     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(96)00048-2     Document Type: Article

References (46)

1. Gendler S, Lancaster C, Taylor-Papadimitriou J, et al. Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J Biol Chem 1990, 265, 15286-15293.
2. Ligtenberg MJL, Vos B, Gennissen A, Hilkens J. Episialin, a carcinoma-associated mucin, is generated by a polymorphic gene encoding splice variants with alternative amino termini. J Biol Chem 1990, 265, 5573-5578.
3. Zotter Z, Hageman PC, Lossnitzer A, Mooi WJ, Hilgers J. Tissue and tumor distribution of human polymorphic epithelial mucin. Cancer Rev 1988, 11-12, 55-101.
4. Price MR, Hudezc F, O'Sullivan C, Baldwin RW, Edwards PM, Tendler SJB. Immunological and structural features of the protein core of human polymorphic epithelial mucin. Mol Immunol 1990, 27, 795-802.
5. Nishimori I, Perini F, Mountjoy KP. N-Acetylgalatosamine glycosylation of MUC1 tandem repeat peptides by pancreatic tumor cell extracts. Cancer Res 1994, 54, 3738-3744.
6. Stadie TRE, Chai W, Lawson AM, Byfield PGH, Hanisch FG. Studies on the order and site specificity of GalNAc transfer to MUC1 tandem repeats by UDP-GalNAc: polypeptide N-acetylgalactosaminyltransferase from milk or mammary carcinoma cells. Eur J Biochem 1995, 229, 140-147.
7. Taylor-Papadimitriou J, Peterson J, Arklie J, Burchell J, Ceriani RL, Bodmer WF. Monoclonal antibodies to epithelium specific components of the human milk fat globule membrane: production and reaction with cells in culture. Int J Cancer 1981, 28, 17-21.
8. Kufe D, Inghirami G, Abe M, Hayes D, Just-Wheeler H, Schlom J. Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma 1984, 3, 223-231.
9. Hilkens J, Buijs F, Hilgers J, et al. Monoclonal antibodies prepared against human milk-fat globule membranes detecting differentiation antigens of the mammary gland and its tumors. Int J Cancer 1984, 34, 197-206.
10. Taylor-Papadimitriou J. Report on the First International Workshop on Carcinoma-Associated Mucin. Int J Cancer 1991, 49, 1-5.
11. Fontenot DJ, Tjandra N, Bu D, Ho C, Montelarco RC, Finn OJ. Biophysical characterization of one-, two-, and three-tandem repeats of human mucine (muc-1) protein core. Cancer Res 1993, 53, 5386-5394.
12. Burchell J, Taylor-Papadimitriou J. Effect of modification of carbohydrate side chains on the reactivity of antibodies with coreprotein epitopes of the MUC1 gene product. Epith Cell Biol 1993, 2, 155-162.
13. Burchell J, Gendler S, Taylor-Papadimitriou J, et al. Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer Res 1987, 47, 5476-5482.
14. Devine PI, Warren JA, Ward BG, McKenzie IFC, Layton GT. Glycosylation and the exposure of tumor-associated epitopes on mucins. J Tumor Marker Oncol 1990, 5, 11-26.
15. Litvinov S, Hilkens J. The epithelial sialomucin, episialin, is sialylated during recycling. J Biol Chem 1993, 268, 21364-21371.
16. Hayes DF, Zurawski VR, Kufe DW. Comparison of circulating CA 15.3 and carcinoembryonic antigen levels in patients with breast cancer. J Clin Oncol 1986, 4, 1542-1550.
17. Bon GG, Kenemans P, van Kamp GJ, Yedema CA, Hilgers J. Review on the clinical value of polymorphic epithelial mucin tumor markers for the management of carcinoma patients. J Nucl Med Allied Sci 1990, 34, 151-162.
18. Hinoda Y, Nakagawa N, Nakamura H, et al. Detection of a circulating antibody against a peptide epitope on a mucin core protein, MUC1, in ulcerative colitis. Immunol Letters 1993, 35, 163-168.
19. Rughetti A, Turchi V, Ghetti CA, et al. Human B-cell immune responses to the polymorphic epithelial mucin. Cancer Res 1993, 53, 2457-2459.
20. Nuti M, Rughetti A, Turchi V, Apolloni-Ghetti C, Scambia G, Frati L. Human B cell immune response to selected epitopes of the polymorphic epithelial mucin (PEM) in cancer patients. In vivo 1993, 7, 645-648.
21. Kotera Y, Fontenot DJ, Pecher G, Metzgar RS, Finn OJ. Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res 1994, 54, 2856-2860.
22. Croce MV, Price MR, Segal-Eiras A. Expression of monoclonal-antibody-defined antigens in fractions isolated from human breast carcinomas and patients' serum. Cancer Immunol Immunother 1995, 40, 132-137.
23. Gourevitch MM, von Mensdorff-Pouilly S, Litvinov SV, et al. Polymorphic epithelial mucin (MUC-l)-containing circulating immune complexes in carcinoma patients. Br J Cancer 1995, 72, 934-938.
24. Hilkens J, Buijs F, Ligtenberg M. Complexity of MAM-6, an epithelial sialo-mucin associated with carcinomas. Cancer Res 1989 ,49 ,786-793.
25. Hilkens J, Kroezen V, Bonfrer JMG, De Jong-Bakker M, Bruning PF. MAM-6, a new serum marker for breast cancer monitoring. Cancer Res 1986, 46, 2582-2587.
26. Hayes DF, Sekine H, Ohno T, Abe M, Keefe K, Kufe DW. Use of a murine monoclonal antibody for detection of circulating plasma DF3 antigen levels in breast cancer patients. J Clin Invest 1985, 75, 1671-1678.
27. Büttner J. Die Beurteilung des diagnostischen Wertes klinischchemischer Untersuchungen. J Clin Chem Clin Biochem 1977, 15, 1-12.
28. Devitt JE. Breast cancer: Have we missed the forest because of the tree? Lancet 1994, 344, 734-735.
29. Braga VMM, Pemberton LF, Duhig T, Gendler SJ. Spatial and temporal expression of an epithelial mucin, Muc-1, during mouse development. Development 1992, 115, 427-437.
30. Hilkens J, Ligtenberg JL, Vos HL, Litvinov S. Cell membrane-associated mucins and their adhesion-modulating property. Trends Biochem Sci 1992, 17, 359-363.
31. Wesseling J, Van der Valk SW, Vos HL, Sonnenberg A, Hilkens J. Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J Cell Biol 1995, 129, 255-265.
32. Van de Wiel-van Kemenade E, Ligtenberg MJL, De Boer AJ, et al. Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction. J Immunol 1993, 151, 767-776.
33. Courtenay-Luck NS, Epenetos AA, Sivalopenko GB, Larche M, Barkans JR, Ritter MA. Development of anti-idiotypic antibodies against tumour antigens and autoantigens in ovarian cancer patients treated intraperitoneally with mouse monoclonal antibodies. Lancet 1988, ii, 894-897.
34. Kosmas C, Epenetos AA, Courtenay-Luck NS. Activation of cellular immunity after intracavitary monoclonal antibody therapy of ovarian cancer. Cancer 1994, 73, 3000-3010.
35. Wagner U, Chronides A, Mallmann P, et al. Induktion einer tumorspezifischen zellulären Immunität durch Idiotypen-Vakzination für das Ovarialkarzinom mit dem MAB OC 125. Tumordiagn u Ther 1993, 14, 125-131.
36. Fagerberg J, Hjelm AL, Ragnhammar P, Frödin JE, Wigzell H, Mellstedt H. Tumor regression in monoclonal antibody-treated patients correlates with the presence of anti-idiotype-reactive T lymphocytes. Cancer Res 1995, 55, 1824-1827.
37. Fagerberg J, Steinitz M, Wigzell H, Askelöf P, Mellstedt H. Human anti-idiotypic antibodies induced a humoral and cellular immune response against a colorectal carcinoma-associated antigen in patients. Proc Natl Acad Sci USA 1995, 92, 4773-4777.
38. Riethmüller G, Schneider-Gädicke E, Schlimok G, et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes'C colorectal carcinoma. Lancet 1994, 343, 1177-1183.
39. Melief CJM. Dendritic cells as specialized antigen presenting cells. Res Immunol 1989, 140, 902-926.
40. Caux Ch, Liu YJ, Banchereau J. Recent advances in the study of dendritic cells and folicular dendritic cells. Immunol Today 1995, 16, 2-4.
41. Barnd DL, Lan MS, Metzgar RS, Finn OJ. Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proc Natl Acad Sci USA 1989, 86, 7159-7163.
42. Jerome KR, Barnd DL, Bendt KM, et al. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res 1991, 51, 2908-2916.
43. Jerome KR, Domenech N, Finn OJ. Tumor-specific cytotoxic T cell clones from patients with breast and pancreatic adenocarcinoma recognize EBV-immortalized B cells transfected with polymorphic epithelial mucin complementary DNA. J Immunol 1993, 151, 1654-1662.
44. Ionnanides CG, Fisk B, Jerome KR, Irimura T, Wharton JT, Finn OJ. Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. J Immunol 1993, 151, 3693-3703.
45. Acres RB, Hareveuni M, Balloul J-M, Kieny M-P. Vaccinia virus MUC1 immunization of mice: immune response and protection against the growth of murine tumors bearing the MUCl antigen. J Immunother 1993, 14, 136-143.
46. Agrawal B, Reddish MA, Krantz MJ, Longenecker BM. Does pregnancy immunize against breast cancer? Cancer Res 1995, 55, 2257-2261.